Erlotinib, a food and drug administration (FDA)-approved EGFR kinase inhibitor for treating EGFR-mutant NSCLC, can reduce CIP2A levels, which indirectly restores the tumor-suppressive activity of PP2A [121]. Here, EGFR is linked to non-small cell lung carcinoma.